Solventum Corporation $SOLV is Nuance Investments LLC’s 7th Largest Position

Nuance Investments LLC reduced its holdings in shares of Solventum Corporation (NYSE:SOLVFree Report) by 21.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 696,967 shares of the company’s stock after selling 186,425 shares during the quarter. Solventum makes up about 5.1% of Nuance Investments LLC’s holdings, making the stock its 7th largest position. Nuance Investments LLC’s holdings in Solventum were worth $50,879,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. CHICAGO TRUST Co NA increased its position in shares of Solventum by 3.0% during the 3rd quarter. CHICAGO TRUST Co NA now owns 5,188 shares of the company’s stock valued at $379,000 after purchasing an additional 150 shares during the last quarter. Applied Finance Capital Management LLC grew its position in Solventum by 3.8% during the second quarter. Applied Finance Capital Management LLC now owns 4,428 shares of the company’s stock valued at $336,000 after buying an additional 162 shares during the period. Lazard Asset Management LLC increased its holdings in Solventum by 1.4% during the second quarter. Lazard Asset Management LLC now owns 11,605 shares of the company’s stock worth $880,000 after buying an additional 163 shares during the last quarter. Deseret Mutual Benefit Administrators increased its holdings in Solventum by 78.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after buying an additional 163 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in Solventum by 2.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 5,963 shares of the company’s stock worth $436,000 after acquiring an additional 166 shares during the period.

Solventum Stock Up 1.6%

Solventum stock opened at $78.20 on Monday. The firm has a 50 day simple moving average of $80.72 and a 200 day simple moving average of $75.96. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03. Solventum Corporation has a 1-year low of $60.70 and a 1-year high of $88.20. The firm has a market capitalization of $13.56 billion, a price-to-earnings ratio of 9.01, a P/E/G ratio of 7.17 and a beta of 0.35.

Solventum (NYSE:SOLVGet Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. The firm had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.05 billion. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The business’s revenue for the quarter was up .7% on a year-over-year basis. During the same period last year, the company earned $1.64 earnings per share. On average, analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum declared that its Board of Directors has approved a stock repurchase program on Thursday, November 20th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the company to buy up to 7.5% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Piper Sandler reissued an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Zacks Research lowered Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. UBS Group restated a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. Finally, Mizuho set a $100.00 price target on Solventum and gave the company an “outperform” rating in a research report on Tuesday, January 20th. Seven research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Solventum presently has a consensus rating of “Hold” and a consensus target price of $90.83.

Get Our Latest Stock Analysis on Solventum

About Solventum

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

Recommended Stories

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLVFree Report).

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.